FiercePharma Articles

•   RSS Feed

Last 50 articles...

• Ireland's Exports Set to Fall Off the Patent Cliff
• Pfizer Plans Direct-to-Consumer Lipitor Sales
• FDA Staffers Back Pfizer's Prevnar Vax for Adults
• AZ's Crestor Scored Points, but Didn't Beat Lipitor
• Has Amgen Crossed Into Big Pharma Territory?
• Pfizer's Strategy for Clinging to Lipitor Sales
• AZ Sales Flat on Generic Rivals, Pricing Pressures
• Abbott Execs Predict Big Growth for Pharma Spinoff
• Pfizer Sues Merck to Block Lipitor/Zetia Combo Pill
• J&J's Doxil Woes Show Shortages Aren't Easily Fixed
• Europe Calls for Limits on Sanofi's Multaq
• J&J Homes In on Flu Med's Return to Stores
• Obama Plan Hits Pharma With Rebates, Pay-to-Delay Ban
• Amgen's Prolia Wins New Uses, Performs in Study
• Pfizer Hints That German Policy Helped Drive 500 Job Cuts
• Novartis Aims to Beat $1.9B in Cost Savings By Year's End
• AstraZeneca's Crestor Fails to Best Lipitor in Study
• Discouraged by Dendreon, Investors Shy From Drug Launches
• Merck, Pfizer Among Cash Stashers as Markets Gyrate
• Pfizer Eyes OTC Lipitor, but Will FDA Approve?
• Pfizer's Drop in Pharma Sales Offset by For-Sale Units
• Forest Lambastes Icahn in Proxy-Fight Letter
• Merck's Plan to Cut 12K More Jobs Aims to Save $1.5B
• J&J Board Blames Woes on Middle Managers, Staff Cuts
• Now That Brilinta's Approved, AZ Has to Sell It
• Merck Gets Roche to Sell HCV Drug in EU, Elsewhere
• Hong Kong Forces Second GSK Recall
• As Advair Sales Erode, Benlysta Gets EMA Nod
• Yervoy May Help BMS Survive European Squeeze
• Gilead First to Jump Into AIDS Patent Pool
• Pfizer Move Disappoints Break-up Champions
• Sanofi's Multaq Takes Hit From Trial Failure
• Lilly Chief Scolds Germany for New Pharma Rules
• Pfizer's Spin-Off Verdict: Generics Yes, Vet Drugs No
• Xarelto Gets a Boost From the FDA
• Musty Smell Touches Off Yet Another J&J Recall
• In Marketing Overhaul, J&J Aims for Integration
• Forest Fights Back Against Icahn in Filing
• Plasticizer Levels Prompt Hong Kong to Yank GSK Drug
• Sweden Approves Copy of GSK Asthma Blockbuster
• Gilead's U.S. Pricing on HIV Meds Draws Fire
• Merck, Teva Near Deal on Generic Vytorin
• J&J, Generics Makers to Revamp Children's Tylenol Products
• Pfizer Profits Beat, but Drug Sales Drop
• Would a Pfizer Break-Up Leave a Healthier Core?
• Blockbuster Expectations for New J&J Prostate Drug
• Lilly Revenue Grows, but Costs Drive Profits Down
• Pfizer, Novartis Drugs Win Advisory Panel Nod
• Novartis, Pfizer See Cancer Data Questioned
• J&J Agrees to Pay $70M in Corruption Probe